Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scotland puts Dx and labs input at centre of new TB action plan

This article was originally published in Clinica

Executive Summary

Scotland has announced a TB Action Plan with a strong focus on “increasing the effectiveness” of diagnostic tests, laboratory services and surveillance activities relating to tuberculosis. The plan, which is targeted at health professionals, is in response to a recently observed rise in TB rates. “Scotland's rate of TB has been relatively low and stable, but recently there has been evidence that the number of cases, while still low, is increasing,” said the Scottish government. “There are various reasons why the number of cases may be increasing, including the emergence of drug resistant strains, the continued prevalence of HIV and increased movement of people between countries,” it added.

You may also be interested in...



Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar

On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.

Everlywell Raises $175M To Expand Consumer Lab Testing, Digital Health

The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel